At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 163 enrolled
Drug / intervention
Pridopidine +1 moredrug
Likely dose
Pridopidine 45mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial - Regimen D Pridopidine
In Brief
A Phase 3 clinical trial evaluating Pridopidine and Matching Placebo for Amyotrophic Lateral Sclerosis. Completed, enrolled 163 participants across 1 site.
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsPrilenia
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionJul 2022
TodayJul 2026
First PostedNov 4, 2020
Enrollment StartDec 18, 2020
Primary CompletionJul 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.7 years ago
Interventions
Pridopidinedrug
Administration: Oral Dose: 45mg twice daily
Matching Placebodrug
Administration: Oral Dose: one capsule twice daily